Intarcia Forgoes Partnerships, Raises $210M In Equity And Debt Instead

Rather than partner its implantable formulation of exenatide, the biotech turned to hedge funds and other non-traditional investors for the year’s largest round of private capital. The deal enables Intarcia to begin Phase III trials on lead program ITCA-650 for type 2 diabetes, which it believes could be a blockbuster.

A year ago, Intarcia Therapeutics Inc. was close to a deal that would have licensed its implantable diabetes drug to a Big Pharma partner. Instead of sharing rights to its compound, however, Intarcia has raised a massive $210 million equity and debt round from private investors, one of the largest in recent memory for a privately-held life sciences company. The new funds will allow it to begin Phase III trials on a program that could see approval by 2016.

In a deal announced Nov. 15, five new investors backed Intarcia with $160 million in equity funding and supplied $50...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

More from North America